Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.

New Hope for Peritoneal Cancer Patients

clinical trial
Sheba and Enlivex Therapeutics began advanced treatment with Allocetra, a drug specifically designed to treat patients with peritoneal carcinoma – a cancer of the membrane that lines much of the abdomen.

Peritoneal cancer is a rare malignancy that develops in the peritoneum, a membrane that lines the walls of the abdominal cavity and rests on the abdominal and pelvic organs. Whether originating from a primary tumor within the peritoneum or a metastatic tumor elsewhere in the body, peritoneal cancer is a terminal disease with a poor prognosis. 

Patients with peritoneal metastases are in urgent need of new treatment alternatives, as standard-of-care chemotherapy currently provides only modest survival benefits. The median survival of patients with peritoneal metastases differs based on the location of the primary tumor, but is frequently poor, with survival rates of 2.9 months, 6.5 months, and 6.9 months reported for cancers of pancreatic, gastric, and colorectal origins, respectively.

Earlier this year, Sheba and Enlivex, a biotech company specializing in macrophage reprogramming immunotherapy, launched a Phase I/II clinical trial for a new cancer treatment called Allocetra. 

Allocetra is a novel immunotherapy in which billions of early apoptotic cells are injected into the patient’s bloodstream, using the body’s own natural regulation mechanisms to rebalance an unbalanced immune system without immunosuppression. With infusion, the body’s macrophages and dendritic cells can feed on these early apoptotic Allocetra cells, causing them to produce fewer cytokine alerts, thus averting a cytokine storm.

Allocetra, designed specifically for the treatment of patients with peritoneal cancer, is used in conjunction with chemotherapy in patients with peritoneal metastases arising from solid tumors.

Prof. Aviram Nissan, M.D., Director of the Department of General Surgery and Surgical Oncology at Sheba and Principal Investigator of the trial, explained: “As part of the trial, Allocetra is administered following pressurized intraperitoneal aerosol chemotherapy (PIPAC), which allows for efficient delivery of therapeutics directly to the peritoneum. We hope that the combination of chemotherapy and Allocetra, a next-generation cell therapy, will generate a breakthrough in the treatment of peritoneal metastases, which are not treatable in most patients today. We are eager to test this new approach with the hope of changing the lives of patients with peritoneal metastases.”  

Breakthrough Research
News Jun 05.
Breakthrough Research Provides Pancreatic Cancer Patients with New Hope
Pancreatic cancer is a significant cause of cancer-related death, standing at fourth place globally. It is also the twelfth most common cancer type worldwide, with…
Read More
Sheba Study in collaboration with other medical institutions found an effective way of treatment, a type of cure for hemophilia.
News Jun 05.
Groundbreaking Sheba Study Indicates: New Gene Therapy Offers Rapid Cure for Hemophilia 
Hemophilia is a bleeding disorder that stems from a genetic mutation or alteration in the genes that encode clotting factor proteins, which are necessary for…
Read More
Sheba and Mayo Clinic merge Data-Sharing Network
News May 18.
Sheba and Mayo Clinic Partner to Transform Patient Care Through an Innovative Data-Sharing Network
Sheba Medical Center has joined the Mayo Clinic Platform Connect, a global data-sharing network that aims to revolutionize healthcare. The groundbreaking platform provides a safe,…
Read More